MAPK3 and neoplasm: In conclusion, our study defines PHOX1 as a methylation-sensitive oncogene in GC, orchestrating tumor progression through transcriptional activation of NGFR, and the PHOX1-NGFR-ERK1/2 axis may serve as a therapeutic target for metastatic GC.